Polymorphic acetylation: lack of influence of rheumatic disease activity and concomitant drug administration

1995 ◽  
Vol 14 (6) ◽  
pp. 257-260
Author(s):  
C. Astbury ◽  
H. A. Bird ◽  
C. Beyeler
Keyword(s):  
Rheumatic Disease ◽  
Disease Activity ◽  
Drug Administration ◽  
Concomitant Drug ◽  
Rheumatic Disease Activity

99mTc-anti-TNF-α scintigraphy in the assessment of rheumatic disease activity

2017 ◽  
Vol 2 (2) ◽  
pp. 31
Author(s):  
Bianca Gutfilen ◽  
SergioAugusto Lopes de Souza ◽  
Gianluca Valentini
Keyword(s):  
Rheumatic Disease ◽  
Disease Activity ◽  
Tnf Α ◽  
Rheumatic Disease Activity

Association of adipokines with rheumatic disease activity indexes and periodontal disease in patients with early rheumatoid arthritis and their first‐degree relatives

2019 ◽  
Vol 22 (11) ◽  
pp. 1990-2000 ◽  
Author(s):  
Jeimy A. Chaparro‐Sanabria ◽  
Wilson Bautista‐Molano ◽  
Juan M. Bello‐Gualtero ◽  
Lorena Chila‐Moreno ◽  
Diana M. Castillo ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatic Disease ◽  
Periodontal Disease ◽  
Disease Activity ◽  
Early Rheumatoid Arthritis ◽  
First Degree Relatives ◽  
Rheumatic Disease Activity

scholarly journals Frequency and Characteristic of Concomitant Fibromyalgia in Patients with Rheumatoid Arthritis

2021 ◽  
Author(s):  
Zi yu Gao ◽  
Zhan hao Chang ◽  
Tian Song ◽  
Dong fan Liu ◽  
Xin Li ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Vitamin D ◽  
Rheumatic Disease ◽  
Disease Activity ◽  
Clinical Data ◽  
Blood Cells ◽  
Similar Pattern ◽  
Confounding Factor ◽  
White Blood Cells ◽  
Rheumatic Disease Activity

Abstract Fibromyalgia (FM) is a confounding factor for diagnosing and assessing rheumatic disease activity. This study sought to assess the extent of this syndrome in rheumatoid arthritis (RA) patients at our rheumatology department. The RA patients were divided into 2 groups (RA with FM and RA without FM) according to the score of the FiRST questionnaire and modified 2016 criteria for FM. We compared the clinical data and disease activities of RA patients with and without FM. As a result, RA patients with FM showed higher levels of CRP, ESR, DAS28-ESR compared with RA patients without FM in both FiRST questionnaires and questionnaires developed to diagnose FM(2016 criteria).Furthermore, RA patients with FM showed higher levels of IgA compared to without FM. For the blood cells count, RA patients with FM showed higher levels of white blood cells, platelets and lower levels of hemoglobin compared with RA patients without FM. Only by FiRST Questionnaires, RA patients with FM showed higher levels of RF compared to without FM. However, all groups showed a similar pattern in anti-CCP and IgG, IgM. RA patients with FM showed lower levels of vitamin D (VD) and higher levels of interleukin (IL)-6 compared with RA patients without FM.In conclusion,FM is a common feature in RA, more associated with high values of disease activity such as ESR, CRP and DAS28-ESR.

scholarly journals Usability and Workflow Evaluation of “RhEumAtic Disease activitY” (READY)

2016 ◽  
Vol 07 (04) ◽  
pp. 1007-1024 ◽  
Author(s):  
Po-Yin Yen ◽  
Barbara Lara ◽  
Marcelo Lopetegui ◽  
Aseem Bharat ◽  
Stacy Ardoin ◽  
...  
Keyword(s):  
Rheumatic Disease ◽  
Disease Activity ◽  
Data Entry ◽  
Usability Evaluation ◽  
Clinical Workflow ◽  
Implementation Phase ◽  
Time Motion ◽  
Usability Problems ◽  
Rheumatic Disease Activity ◽  
The Impact

SummaryBackground RhEumAtic Disease activitY (READY) is a mobile health (mHealth) application that aims to create a shared platform integrating data from both patients and physicians, with a particular emphasis on arthritis disease activity.Methods We made READY available on an iPad and pilot implemented it at a rheumatology outpatient clinic. We conducted 1) a usability evaluation study to explore patients’ and physicians’ interactions with READY, and 2) a time motion study (TMS) to observe the clinical workflow before and after the implementation.Results A total of 33 patients and 15 physicians participated in the usability evaluation. We found usability problems in navigation, data entry, pain assessment, documentation, and instructions along with error messages. Despite these issues, 25 (75,76%) patients reported they liked READY. Physicians provided mixed feedback because they were concerned about the impact of READY on clinical workflow. Six physicians participated in the TMS. We observed 47 patient visits (44.72 hours) in the pre-implementation phase, and 42 patient visits (37.82 hours) in the post-implementation phase. We found that patients spent more time on READY than paper (4.39mins vs. 2.26mins), but overall, READY did not delay the workflow (pre = 52.08 mins vs. post = 45.46 mins). This time difference may be compensated with READY eliminating a workflow step for the staff.Conclusion Patients preferred READY to paper documents. Many found it easier to input information because of the larger font size and the ease of ‘tapping’ rather than writing-out or circling answers. Even though patients spent more time on READY than using paper documents, the longer usage of READY was mainly due to when troubleshooting was needed. Most patients did not have problems after receiving initial support from the staff. This study not only enabled improvements to the software but also serves as good reference for other researchers or institutional decision makers who are interested in implementing such a technology.Citation: Yen P, Lara B, Lopetegui M, Bharat A, Ardoin S, Johnson B, Mathur P, Embi P, Curtis J. Usability and workflow evaluation of “RhEumAtic Disease activitY” (READY).

scholarly journals Storage Conditions of Immunobiologicals and their Influence on the Efficacy and Safety in the Treatment of Autoimmune Rheumatic Diseases

2020 ◽  
Vol 14 (1) ◽  
pp. 1-6
Author(s):  
Tássia Moraes de Assis Damasce ◽  
Vander Fernand ◽  
Cristhiane Almeida Leite da Silva ◽  
Ageo Mario Candido da Silva ◽  
Luciana Carolina Ishikawa Cezar Santo ◽  
...  
Keyword(s):  
Rheumatic Disease ◽  
Disease Activity ◽  
Rheumatic Diseases ◽  
Storage Temperature ◽  
Efficacy And Safety ◽  
Mato Grosso ◽  
Temperature Range ◽  
Autoimmune Rheumatic Diseases ◽  
Autoimmune Rheumatic Disease ◽  
Rheumatic Disease Activity

Objective: The study aimed to evaluate the influence of storage temperature on immunobiological efficacy and safety in autoimmune rheumatic disease treatment. Methods: This observational study included adult patients with autoimmune rheumatic diseases who used immunobiologicals stored at home and were followed up at the rheumatology outpatient clinic of the General University Hospital of Cuiabá, Mato Grosso, Brazil, in 2017/2018. Patients were evaluated regarding disease activity and occurrence of adverse events, and a household survey of the temperature of the storage environment of these drugs was conducted. Results: Sixty patients with a mean age of 50.4 years were evaluated. Of these, 39 patients (65%) stored their biological drugs outside the recommended temperature range. Storage of the immunobiological at the incorrect temperature was 76% higher among patients with moderate/high rheumatic disease activity (p=0.003). Conclusion: Most patients stored their immunobiologicals outside the temperature range recommended in the package insert, and there was an association between incorrect storage temperature and moderate/high autoimmune rheumatic disease activity.

P024 Efficacy and tolerance of methotrexate in patients with Juvenile Idiopathic Arthritis

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_5) ◽  
Author(s):  
A Fazaa ◽  
F Rouatbi ◽  
S Miladi ◽  
K Ouenniche ◽  
L Souabni ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Rheumatic Disease ◽  
Disease Activity ◽  
Treatment Duration ◽  
Therapeutic Management ◽  
Weekly Dose ◽  
Highly Active ◽  
Oral Corticosteroid Therapy ◽  
Hepatic Cytolysis ◽  
International League

Abstract Background Juvenile idiopathic arthritis (JIA) is the most common inflammatory rheumatic disease for children. The therapeutic management depends on several factors and is based on different treatments including methotrexate (MTX). The aim of our study was to determine the efficacy and safety of MTX in JIA. Methods This is a monocentric retrospective study of 37 patients followed for JIA according to the 2001 International League of Association of Rheumatology (ILAR) criteria and treated with MTX. Socio-demographic, clinical, paraclinical and therapeutic data were collected. Disease activity was assessed by the JADAS score. Highly active JIA was defined as JADAS superior to 25. Results There were 25 boys (67.5%) and 12 girls (32.4%) with a median age of 6.3 years [4–13]. The average duration of the rheumatic disease was 2.7 years [2.5–5.3]. The type of JIA was: oligoarticular in 22 cases (59.4%), polyarticular in 10 cases (27%), arthritis related to enthesitis in 3 cases (8.1%) and systemic in 2 cases (5.4%). Twenty patients (54%) received oral corticosteroid therapy for a mean period of 1.7 years [0.6–3] with a mean daily dose of 10 mg/day of prednisone or equivalent. Oral MTX was prescribed to all patients with a mean weekly dose of 10 mg/m2 body surface [10–15]. MTX was initiated after a mean period of 6.2 months [3.1–11.4] from diagnosis. The mean treatment duration was 50 months [34–66]. Observance of MTX was 80.5%. Remission with MTX was achieved in 28 patients (75.6%) after a mean treatment duration of 7.5 months [5–11], with a mean JADAS of 5.1 [3.5–10]. Despite good observance of MTX, eight patients (21.6%) continued to have high disease activity with a mean JADAS score of 32 [25–40]. Tolerance to oral MTX was good, with side effects occurring only with 5 patients (13.5%), such as epigastralgia in 2 cases (which disappeared after switching to the intramuscular administration), a skin reaction in one case, and hepatic cytolysis reversible when stopping the treatment in 2 other cases. Conclusion MTX still has a place in the therapeutic management of JIA and appears to be a well-tolerated and effective treatment.

Sign in / Sign up

Export Citation Format

Share Document